What is the rationale for novel combination therapies?
Niels van de Donk
What is the role for idelalisib and duvelisib in CLL?
Highlights from EHA 2016 press briefings: POLLUX and EURO-SKI trials and BiTE antibodies
Why it is important to individualize care for multiple myeloma patients
Smouldering myeloma: detection, risk stratification and defining a new standard of care